Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2008

View Archived Issues

Coffee, tea reduce cerebral infarction risk in male smokers

Caloric intake reduced with AC-2307 in obese subjects

ARISE trial data, mechanism of action study reported for AGI-1067

Benefits seen with metreleptin in patients with nonalcoholic steatohepatitis

Pfizer launches Toviaz once-daily treatment for the symptoms of overactive bladder

Gemin X closes series C financing to advance registration of obatoclax

FDA grants DuoCort orphan drug designation for adrenal insufficiency

FDA grants orphan drug designation for Marqibo in metastatic uveal melanoma

EMEA accepts for review UCB's MAA for Cimzia in rheumatoid arthritis

Repros initiates phase IIb comparative study of Androxal and Testim for male fertility

Halozyme reports positive results from phase I/IIa clinical trial of Chemophase

Genmab receives milestone payment from GSK for initiation of phase II study of ofatumumab

FDA accepts for review Acusphere's NDA for Imagify in coronary artery disease

Alpharma resubmits NDA for Embeda to FDA

PM-00104 shows preclinical activity against multiple myeloma via induction of p53

Roche reports results from pilot study of NT-proBNP in predicting CV-AE

GSK presents update on application to FDA for approval of cervical cancer vaccine Cervarix

FDA approves VGX's IND application for VGX-3100 DNA vaccine for cervical cancer

XTL completes patient randomization into phase IIb study of bicifadine

Epix resubmits Vasovist NDA to FDA

Ore files IND application with FDA for GL-1001 in inflammatory bowel disease

Preliminary response rate data reported for discontinued phase III trial of CoFactor

New agents for Alzheimer's disease and other neurological disorders reported in recent patents

Lev to submit Cinryze application to the EMEA for hereditary angioedema

New antiobesity agents claimed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...